Companies › Prokidney
1 active drug program in 1 registered trial: 1 Phase 3; Genitourinary; next expected readout Dec 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| rilparencel (REACT) Renal autologous cell therapy | – | Phase 3 | Type 2 Diabetes Mellitus | Dec 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05099770 | rilparencel (REACT) | Phase 3 | Type 2 Diabetes Mellitus | Genitourinary | Dec 2029 |
Cash of $75m on 2026-06-30; operating cash outflow about $166m a year; runway about 5 months at that burn, to Dec 2026; 0 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
No annotated target.
–
Urotronic Cisen Pharmaceutical Levee Medical YolTech Therapeutics Vera Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.